Sir, The widespread dissemination of acquired carbapenemhydrolysing enzymes, particularly Ambler classes B
[metallo-b-lactamases (MBLs)] and D (oxacillinases), is of great clinical concern. Of the MBLs, the IMP and VIM types are the most frequent, with more than 20 countries reporting their presence. 1 The VIM-4 enzyme was first described from a Pseudomonas aeruginosa isolate from Larissa, Greece, 2 and, soon after, an outbreak occurred at that institution. The bla VIM-4 gene has also been reported from Italy and Poland, but thus far there have been no reports from Australia. 1 The class D carbapenemases are now divided into four distinct phylogenetic clusters: OXA-23 (OXA-23 and OXA-27), OXA-24 (OXA-24, OXA-25, OXA-26 and OXA-40), OXA-58 and OXA-51. OXA-58 has recently been shown to contribute significantly to carbapenem resistance in Acinetobacter baumannii, especially when additional efflux mechanisms are expressed. 3 This enzyme has now been reported from France, Spain, Turkey and Romania, and, more recently, from Australia 4 and Greece. 5 The role of international travel in the global dissemination of carbapenemase genes is often reported, but rarely has this been well illustrated. 6 In October 2005, a 35-year-old female underwent an interhospital, inter-country transfer from an intensive care unit (ICU) in Athens, Greece, to our ICU. Five weeks before she had been hit by a car while walking and sustained multiple injuries, including an intra-cranial haemorrhage and long bone fractures. She remained in the ICU in Greece until transfer and was intubated and ventilated for 23 days. On arrival the patient had a central venous catheter (CVC), a radial arterial line, a urinary catheter and a tracheostomy in situ. Within 12 h of transfer, high fever developed with no clinical source of infection identified. Blood and urine cultures were obtained. Vascular lines and the urinary catheter were removed, empirical teicoplanin and tobramycin were started and strict infection control precautions were initiated.
The following day, P. aeruginosa was identified from urine cultures in the absence of significant pyuria. Susceptibility testing was performed using broth microdilution according to CLSI standards. The isolate was susceptible only to polymyxin B and was resistant to meropenem
, ticarcillin/clavulanate (MIC > 128 mg/L) and ciprofloxacin (MIC > 4 mg/L). The CVC tip cultures were also positive for a carbapenem-resistant A. baumannii, and this was soon followed (>2 h) by positive peripheral blood cultures for the same organism. These isolates were resistant to all tested antibiotics except for polymyxin B. The patient became afebrile within 72 h and all antibiotics were ceased. Recovery was made and no further infective complications ensued. Nosocomial transmission was not identified.
An Etest Ò MBL (AB Biodisk, Solna, Sweden) was performed on both Gram-negative genera, with the P. aeruginosa isolate testing positive according to the manufacturer's guidelines. To confirm the mechanism of carbapenem resistance the isolates underwent PCR testing for the detection of bla IMP and bla VIM MBL genes and class D carbapenemase genes (OXA-23 and OXA-24 cluster and OXA-58). Amplification products were identified for bla VIM in the P. aeruginosa isolate and bla OXA-58 in the A. baumannii isolate. Nucleotide sequencing confirmed the presence of the bla VIM-4 and bla OXA-58 genes in the P. aeruginosa and A. baumannii isolates, respectively, with a complete sequence identified for each gene.
To our knowledge, this is the first report of a bla VIM gene in Australia. bla IMP-4 -carrying Gram-negative organisms have led to a significant outbreak in our geographic region, 8 but the introduction of a second MBL type is a matter of concern. The finding of a bla OXA-58 -carrying A. baumannii is of interest, as this gene has only recently been reported from an ICU in Athens, Greece. 5 This case highlights the importance of international travel in the spread of antimicrobial resistance. The global emergence of carbapenemase genes is worrying and we believe that consideration should be given to isolating and screening all patients admitted to hospital from a foreign country for multidrug-resistant pathogens. 1 Various factors, including the age of the recipient, stem cell dose (CD34+ cells), source of stem cells (bone marrow versus mobilized blood stem cells), degree of HLA matching, administration of colony stimulating factors, T cell depletion and infections, are known to affect the process of engraftment. 1, 2 Vancomycin is commonly used during the course of haematopoietic transplantation. Although vancomycin-induced neutropenia has been reported, 3, 4 in the presence of other confounding factors such as infection, sepsis and other antibiotics, a direct causal relationship may be difficult to establish. We herein report a case of rapid megakaryocytic engraftment with normalization of platelet counts in the absence of myeloid engraftment and restoration of myeloid haematopoiesis following discontinuation of vancomycin.
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A 59-year-old male received a non-myeloablative allogeneic haematopoietic stem cell transplant (allo-SCT) for intermediate risk (normal cytogenetics) acute myelogenous leukaemia (AML-M4) in first complete remission (CR 1 ) from a 6/6 HLAmatched unrelated donor. A total of 6.1 · 10 6 CD34+ cells were infused following sub-ablative conditioning (busulfan 0.8 mg/kg every 6 h · 2 days, fludarabine 30 mg/m 2 · 3 days and alemtuzumab 10 mg · 5 days). Graft versus host disease (GVHD) prophylaxis was performed with a short course of methotrexate (10 mg/m 2 on day +1; 5 mg/m 2 on day +3; and 5 mg/m 2 on day +6) and tacrolimus. The transplant course was uncomplicated except for a catheter-insertion-site infection on day +12, for which intravenous vancomycin (1 g every 12 h) was initiated. The peak and trough vancomycin levels were 27.1 mg/L (range = 30.0-40.0 mg/L) and 8.4 mg/L (range = 5.0-10.0 mg/L), respectively. The patient remained afebrile, blood cultures were negative and he did not receive any other antibiotic. Figure 1 demonstrates the neutrophil and platelet nadir along with the haematopoietic reconstitution. Megakaryocytic engraftment (platelets >20 000/dL · 3 consecutive days in the absence of transfusion) occurred on day +10 without myeloid engraftment. On day +18 colony stimulating factor (G-CSF; 480 mg subcutaneously daily) was initiated. On day +19 the platelet count was 160 000/dL without any evidence of myeloid engraftment (neutrophils = 2, WBC = 100/dL). On day +21, vancomycin was discontinued; myeloid engraftment occurred on day +23 (13 days after megakaryocytic engraftment). An absolute lymphocyte count (ALC) at myeloid engraftment was 18 cells/mm 3 . Lymphocyte recovery (ALC ‡ 500 cells/mm 3 ) occurred in 70 days. Engraftment studies on day 30 confirmed 99.5% donor chimerism. Pre-emptive ganciclovir was initiated for cytomegalovirus (CMV) antigenaemia
